Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis, Characterization and Binding Studies of Polymeric Nanoparticles using Gemcitabine Hydrochloride

Author(s): Velisha Mehta, Y.C. Mayur, Maushmi S. Kumar* and Divya Suares

Volume 13, Issue 2, 2023

Published on: 01 August, 2023

Page: [102 - 112] Pages: 11

DOI: 10.2174/2468187313666230727162613

Price: $65

Abstract

Background: Gemcitabine is a clinically valuable drug delivered intravenously. In order to explore other routes of administration for more efficacious drug delivery, its redevelopment for application through oral route with the help of nanotechnology is an ongoing thrust area. Nanotechnology helps the drug enter into tissues at the molecular level, with increased drug localisation and cellular uptake, larger surface area with modifiable biologic properties, mediate molecular interactions and identify molecular changes.

Objective: The objective of the study was to use Eudragit RS100 to prepare polymeric nanoparticles of gemcitabine (GEM) in order to improve its half-life, reduce dosage and increase the stability of the drug.

Methods: GEM polymeric nanoparticles were prepared by nanoprecipitation technique. They were characterized for particle size, zeta potential (ZP), drug content, entrapment efficiency (EE) and invitro drug release. Further, they were also evaluated using TEM, DSC and FTIR spectroscopy. Mechanistic insights of the synthesized nanoparticles were explored using a protein binding study, electrophoretic mobility shift assay (EMSA) and plasma protein binding study. Docking study was carried out to check the binding of the drug and polymer with DNA and protein.

Results: The synthesized GEM polymeric nanoparticles showed particle size in the range of 200- 450 nm. Due to physical stability issues, optimized polymeric nanoparticles of GEM were lyophilized and exhibited a zeta potential of +11.9 mV, drug content 96.74% w/v and EE of 68-75% w/v. In-vitro drug release study demonstrated sustained release. Protein binding study with bovine serum albumin (BSA) revealed protein binding of GEM-loaded polymeric nanoparticles comparable with the marketed formulation (Oncogem 200, Cipla Ltd.). In addition to this, human plasma protein binding studies showed negligible interaction of GEM with plasma proteins with both formulations. EMSA displayed binding with CT-DNA.

Conclusion: Lyophilized GEM nanoparticles were found to be stable and the mechanistic studies found them comparable to that of marketed formulation.

Next »
Graphical Abstract

[1]
Tannock IF. Conventional cancer therapy: Promise broken or promise delayed? Lancet 1998; 351(2): SII9-SII16.
[http://dx.doi.org/10.1016/S0140-6736(98)90327-0] [PMID: 9606361]
[2]
Patel DJ, Mistri PA, Prajapati JJ. Treatment of cancer by using nanoparticles as a drug delivery. Int J Drug Dev Res 2012; 4: 14-27.
[PMID: 22154931]
[3]
Arias JL, Reddy LH, Couvreur P. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target 2009; 17(8): 586-98.
[http://dx.doi.org/10.1080/10611860903105739] [PMID: 19694612]
[4]
Parveen S, Misra R, Sahoo SK. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012; 8(2): 147-66.
[http://dx.doi.org/10.1016/j.nano.2011.05.016] [PMID: 21703993]
[5]
Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm 2007; 33(2): 101-11.
[http://dx.doi.org/10.1080/03639040601096695] [PMID: 17454041]
[6]
Das S, Suresh PK, Desmukh R, Desmukh R, Pharm M. Design of eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine 2010; 6(2): 318-23.
[http://dx.doi.org/10.1016/j.nano.2009.09.002] [PMID: 19800990]
[7]
Joshi M. Role of eudragit in targeted drug delivery. Int J Curr Pharm Res 2013; 5(2): 58-62.
[8]
Pignatello R, Bucolo C, Puglisi G. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 2002; 91(12): 2636-41.
[http://dx.doi.org/10.1002/jps.10227] [PMID: 12434408]
[9]
Momoh MA, Kenechukwu FC, Adedokun MO, Odo CE, Attama AA. Pharmacodynamics of diclofenac from novel eudragit entrapped microspheres. Drug Deliv 2014; 21(3): 193-203.
[http://dx.doi.org/10.3109/10717544.2013.843608] [PMID: 24171400]
[10]
Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999; 25(4): 471-6.
[http://dx.doi.org/10.1081/DDC-100102197] [PMID: 10194602]
[11]
Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009; 26(5): 1025-58.
[http://dx.doi.org/10.1007/s11095-008-9800-3] [PMID: 19107579]
[12]
Krishnamoorthy K, Mahalingam M. Selection of a suitable method for the preparation of polymeric nanoparticles: Multi-criteria decision making approach. Adv Pharm Bull 2015; 5(1): 57-67.
[PMID: 25789220]
[13]
Miladi K, Sfar S, Fessi H, Elaissari A. Nanoprecipitation process: From particle preparation to in vivo applications.Polymer Nanoparticles for Nanomedicines. Cham: Springer 2016; p. 17-53.
[http://dx.doi.org/10.1007/978-3-319-41421-8_2]
[14]
Yalcin TE, Ilbasmis-Tamer S, Takka S. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo. Int J Pharm 2020; 580: 119246.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119246] [PMID: 32205141]
[15]
Bhattacharya S, Anjum MM, Patel KK. Gemcitabine cationic polymeric nanoparticles against ovarian cancer: Formulation, characterization, and targeted drug delivery. Drug Deliv 2022; 29(1): 1060-74.
[http://dx.doi.org/10.1080/10717544.2022.2058645] [PMID: 35363113]
[16]
García-García G, Fernández-Álvarez F, Cabeza L, et al. Gemcitabine-loaded magnetically responsive poly(ε-caprolactone) nanoparticles against breast cancer. Polymers 2020; 12(12): 2790-802.
[http://dx.doi.org/10.3390/polym12122790] [PMID: 33255803]
[17]
Cai H, Wang R, Guo X, et al. Combining gemcitabine-loaded macrophage-like nanoparticles and erlotinib for pancreatic cancer therapy. Mol Pharm 2021; 18(7): 2495-506.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c01225] [PMID: 34078087]
[18]
Malfanti A, Miletto I, Bottinelli E, Zonari D, Blandino G, Berlier G. Delivery of gemcitabine prodrugs employing mesoporous silica nanoparticles. Molecules 2016; 21(21): 522.
[19]
Papa AL, Basu S, Sengupta P, Banerjee D, Sengupta S, Harfouche R. mechanistic studies of gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer 2012; 12(1): 419.
[http://dx.doi.org/10.1186/1471-2407-12-419] [PMID: 22998550]
[20]
Arias JL, Gallardo V, Ruiz MA. Engineering of poly (butyl cyanoacrylate) nano- particles for the enhancement of the antitumor activity of gemcitabine. Biomacromol 2011; 12(9): 3350.
[21]
Li H. Molecular modeling and spectroscopic studies on the interaction of transresveratrol with bovine serum albumin. J Chem 2013; 7.
[22]
Wani TA, Bakheit AH, Abounassif MA, Zargar S. Study of interactions of an anticancer drug neratinib with bovine serum albumin: Spectroscopic and molecular docking approach. Front Chem 2018; 6: 47.
[http://dx.doi.org/10.3389/fchem.2018.00047] [PMID: 29564326]
[23]
Zhang X. Protein binding determination of DHA in human plasma by HPLC using post-column on-line alkali derivatization and UV detection. In: PhD Thesis. Goteborg, Sweden: Chalmers University of Technology 2010.
[24]
Usman A, Ahmad M. Binding of Bisphenol-F, a bisphenol analogue, to calf thymus DNA by multi-spectroscopic and molecular docking studies. Chemosphere 2017; 181: 536-43.
[http://dx.doi.org/10.1016/j.chemosphere.2017.04.115] [PMID: 28463728]
[25]
Cheng Z, Liu R. Spectroscopic studies on the interaction between tetrandrine and two serum alb. Spectrochim. Acta Part A Mol. Biomol Spectrosc 2016; 115: 92-105.
[http://dx.doi.org/10.1016/j.saa.2013.06.007]
[26]
Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nat Protoc 2007; 2(8): 1849-61.
[http://dx.doi.org/10.1038/nprot.2007.249] [PMID: 17703195]
[27]
Gaudin A, Song E, King AR, et al. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016; 105: 136-44.
[http://dx.doi.org/10.1016/j.biomaterials.2016.07.037] [PMID: 27521616]
[28]
Jelvehgari M, Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Kiafar F. Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles. Res Pharm Sci 2017; 12(1): 1-14.
[http://dx.doi.org/10.4103/1735-5362.199041] [PMID: 28255308]
[29]
Kandagal PB, Ashoka S, Seetharamappa J, Shaikh SMT, Jadegoud Y, Ijare OB. Study of the interaction of an anticancer drug with human and bovine serum albumin: Spectroscopic approach. J Pharm Biomed Anal 2006; 41(2): 393-9.
[http://dx.doi.org/10.1016/j.jpba.2005.11.037] [PMID: 16413740]
[30]
Suryawanshi VD, Walekar LS, Gore AH, Anbhule PV, Kolekar GB. Spectroscopic analysis on the binding interaction of biologically active pyrimidine derivative with bovine serum albumin. J Pharm Anal 2016; 6(1): 56-63.
[http://dx.doi.org/10.1016/j.jpha.2015.07.001] [PMID: 29403963]
[31]
Iranfar H, Rajabi O, Salari R, Chamani J. Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: Multispectroscopic and ζ potential investigation. J Phys Chem B 2012; 116(6): 1951-64.
[http://dx.doi.org/10.1021/jp210685q] [PMID: 22224861]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy